Clinical Trial

A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

Name: A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies — clinical trial record (NCT07735533)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).

Trial Details

NCT Number	NCT07735533
Lead Sponsor	Umoja Biopharma
Conditions	Lymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma, Richter Transformation Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Enrollment	274 participants
Start Date	2026-08
Primary Completion	2031-08 (estimated)
Study Completion	2031-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-30